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Abstract 
Introduction  
Few original studies have described prevalence and severity of clinical symptoms of primary 
ciliary dyskinesia (PCD). This systematic review and meta-analysis aimed to identify all 
published studies on clinical manifestations of PCD patients, and to describe their prevalence 
and severity stratified by age and sex. 
Methods  
We searched PubMed, Embase and Scopus for studies describing clinical symptoms of ≥10 
patients with PCD. We performed meta-analyses and meta-regression to explain heterogeneity. 
Results  
We included 52 studies describing a total of 1970 patients (range 10-168 per study).  We found 
a prevalence of 5% for congenital heart disease. For the rest of reported characteristics, we 
found considerable heterogeneity (I2 range: 68-93.8%) when calculating the weighted mean 
prevalence. Even after taking into account the explanatory factors, the largest part of the 
between-studies variance in symptom prevalence remained unexplained for all symptoms. 
Sensitivity analysis including only studies with test-proven diagnosis showed similar results in 
prevalence and heterogeneity. 
Conclusion  
Large differences in study design, selection of study populations and definition of symptoms 
could explain the heterogeneity in symptom prevalence. To better characterise the disease, we 
need larger, multicenter, multidisciplinary, prospective studies that include all age groups, use 
uniform diagnostics and report on all symptoms. 
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Introduction 
Primary ciliary dyskinesia (PCD) is a rare inherited disease which affects ciliary structure and 
function. As with most orphan diseases, PCD research has focused on pathology and 
diagnostics. PCD leads to severely impaired mucociliary clearance and a wide variety of 
symptoms primarily affecting the respiratory system.[1] Productive cough, rhinitis and recurrent 
infections of the upper and lower respiratory tract have been described as leading 
symptoms.[2,3] Manifestations from other systems have also been reported and about half of the 
patients have been described to present with situs inversus.[4] In addition, many men with PCD 
have immobile spermatozoa or dysfunction of cilia in the epididymal duct leading to infertility.[5] 
The prevalence of the disease is estimated between 1:2,000 and 1:40,000 [3] but the disease is 
underdiagnosed.[6] 
Information about clinical symptoms of PCD is derived mainly from case series and non-
systematic reviews reflecting expert opinion. There are few original studies which mostly include 
a small study population, consisting primarily of paediatric patients. Original publications 
describing the full spectrum of symptoms are scarce and there are few data on less common 
symptoms. In many diseases it is known that symptoms evolve and change with age but few 
studies describe how symptoms have changed over time and PCD patients for different age 
groups. PCD patients compose a relatively heterogeneous group, as diagnostics and 
management approaches vary between centres. [1,7] PCD diagnosis is still not uniform 
internationally and most recommended tests are not available in many centres and countries, so 
clinical manifestations continue to play an important role in the diagnosis of PCD.  
In this systematic review and meta-analysis, we aimed to identify all published studies 
presenting clinical symptoms and signs in PCD patients and to describe the reported prevalence 
of all clinical manifestations. This includes the prevalence of upper and lower respiratory 
symptoms as well as less common clinical findings. We also aimed to describe differences in 
prevalence and severity of findings in different age groups.  
Methods 
We developed a protocol for the systematic review beforehand which is described in the 
following sections. 
Search strategy  
We searched the online databases PubMed, Embase and Scopus to identify studies describing 
clinical manifestations in patients with PCD. In order to build a search term that would identify as 
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many studies as possible, we first performed a pilot search. We searched for studies that were 
published between January 1980 and April 2015 including published abstracts. We conducted 
this search without any restrictions in language or study design.  
The search was performed with the following terms: 
PubMed: (((((("kartagener syndrome"[tiab]) OR ("primary ciliary dyskinesia"[tiab]) OR ("ciliary 
motility disorder"[tiab]) OR ("immotile cilia syndrome"[tiab])) OR ("Ciliary Motility Disorders"[mh])) 
AND ("clinical symptoms" OR "clinical manifestations" OR "clinical presentation")) OR 
(((("kartagener syndrome"[tiab]) OR ("primary ciliary dyskinesia"[tiab]) OR ("ciliary motility 
disorder"[tiab]) OR ("immotile cilia syndrome"[tiab])) OR ("Ciliary Motility Disorders"[mh])) AND 
(patients[tiab] OR subjects[tiab] OR participants[tiab] OR "cases"[tiab])) AND 
(("1980/01/01"[PDat] : "2015/04/30"[PDat])))) 
Embase: 'primary ciliary dyskinesia'/syn OR 'primary ciliary dyskinesia' OR 'kartagener 
syndrome'/syn OR 'kartagener syndrome' AND ('clinical symptoms':ab OR 'clinical 
manifestations':ab OR 'clinical presentation':ab OR patients:ab OR subjects:ab OR cases:ab OR 
participants:ab) AND ([article]/lim OR [article in press]/lim OR [conference abstract]/lim OR 
[conference paper]/lim) AND [1980-2015]/py 
Scopus: (((TITLE-ABS-KEY(primary ciliary dyskinesia) AND PUBYEAR > 1979) OR (TITLE-
ABS-KEY(immotile cilia syndrome) AND PUBYEAR > 1979) OR (TITLE-ABS-KEY(kartagener 
syndrome) AND PUBYEAR > 1979)) AND (TITLE-ABS-KEY("clinical symptoms" OR "clinical 
manifestations" OR "clinical presentation") AND PUBYEAR > 1979)) OR (((TITLE-ABS-
KEY(primary ciliary dyskinesia) AND PUBYEAR > 1979) OR (TITLE-ABS-KEY(immotile cilia 
syndrome) AND PUBYEAR > 1979) OR (TITLE-ABS-KEY(kartagener syndrome) AND 
PUBYEAR > 1979)) AND (TITLE-ABS-KEY(patients OR subjects OR participants OR cases) 
AND PUBYEAR > 1979)) 
After identifying all eligible studies, we checked for additional citations in their reference lists. We 
used the Endnote X5 citation manager.  
Definition of PCD patients  
We defined PCD patients as all patients reported by the authors as being diagnosed with PCD. 
This included a wide range of inclusion criteria, ranging from patients with a clinical diagnosis to 
those with positive results from the different available diagnostic tests (electron microscopy 
(EM), light or high speed video-microscopy (VM), nasal NO (nNO) and genetics). 
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Study selection 
We included studies containing information on clinical manifestations of patients with PCD with a 
study population of 10 or more individuals. We excluded publications based on the following 
exclusion criteria: not original studies, studies that were not topic related or did not contain any 
clinical information (e.g. describing diagnostics, genetics), and studies describing other rare 
ciliary syndromes such as Joubert or Meckel-Gruber syndrome. 
We decided on the inclusion initially by screening the titles and abstracts. From our pilot search 
we realized that many studies containing information on clinical manifestations did not explicitly 
articulate this in the title or abstract. For this reason, we decided to also screen the full text of all 
studies which described an original study population of PCD patients and thus had a high 
probability to contain clinical information in the full text, even if it was not mentioned in the title or 
abstract. After reading the full text of all potentially eligible studies, the final decision on whether 
to include them in the review or not, was made by two reviewers. During the final step of 
inclusion, we excluded studies that did not contain any clinical information. The two reviewers 
decided independently, and in case of disagreement, a consensus decision was reached after 
discussion. 
Overlapping study population 
We identified all studies which might have described the same study population, in order to 
avoid including the same patients multiple times in our review. We compared the author list, 
country of origin and department where the study took place and when we noticed a 
considerable overlap in the study population, we always included in the quantitative synthesis 
the study that was published most recently and included information on a larger number of 
patients and/or more clinical manifestations. When the studies were published 10 or more years 
apart, we included them both, as we believe there was little chance of significant overlap. Where 
the possibility of an overlap was not clear, we contacted the investigators to clarify it. 
Data extraction 
Using the software Epidata 3.1, we extracted the following information from all studies, including 
the ones with overlapping population: author and publication specific information, study 
characteristics, information on reported clinical manifestations of PCD patients. Specifically, we 
extracted publication details (e.g. author names, journal and year of publication, country and 
centre of corresponding author) and study characteristics (e.g. years of study performance, 
study design, inclusion and exclusion criteria, study population size, country where the study 
7 
 
took place, type of clinic, age of participants and age stratification of clinical manifestations). 
Secondly, we extracted extensive information on all reported clinical manifestations of PCD 
patients such as situs inversus, lower and upper respiratory symptoms, neonatal symptoms and 
other non-respiratory findings (e.g. congenital heart disease, infertility). We extracted the number 
of affected individuals in each study and calculated the prevalence of the reported clinical 
manifestations. Where only percentages of affected patients were given, we calculated the 
number of patients affected and then the prevalence. 
Meta-analysis 
We used a random effects model for binomial data to perform meta-analyses on the transformed 
prevalence (Freeman-Tukey Double arcsine transformation) of clinical manifestations[8-10] and 
to assess the heterogeneity (I2) between studies.[11] Diagnosis of PCD has significantly evolved 
overtime and could have influenced the characteristics of the patients included in the eligible 
studies. Therefore, we performed also subgroup meta-analyses, which excluded studies where 
PCD diagnosis was based only on clinical manifestations or where information on diagnostics 
were not available.  
To investigate reasons for heterogeneity we then fitted meta-regression models considering the 
following explanatory factors one at a time:  type of clinic (general paediatrics, paediatric 
pulmonology, adult pulmonology, Ear-Nose-Throat (ENT) clinic or other), age of patients (adults, 
children or both), publication year (published ≤1994, 1995-2004 and ≥2005), number of patients 
included (<20, 21-50, 51-100 and >100 patients), study design (retrospective or prospective) and 
level of diagnostic certainty (clinical diagnosis, diagnosis proven by EM, or diagnosis proven by 
combination of EM and other tests (VM, nNO or genetics). Studies in which the inclusion criteria 
influenced the prevalence of some clinical manifestations were excluded from the meta-analyses 
and meta-regression for these characteristics. For instance, studies describing patients with 
Kartagener syndrome were excluded from the meta-analyses on prevalence of situs anomalies, 
bronchiectasis and sinusitis. We also excluded these studies from the meta-analysis on 
prevalence of congenital heart disease as patients with situs anomalies have a higher probability 
to have congenital heart disease than patients with situs solitus. Statistical analysis was 
performed with R software version 3.2 using the meta package (version 4.2) and specifically the 
commands metaprop and metareg. 
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Results 
Search 
After excluding duplicates identified by more than one database (Pubmed, Embase, Scopus) our 
search identified 1210 articles (Figure 1). First, we screened for inclusion and exclusion criteria 
by reading through titles and abstracts and excluded 1109 articles. For 16 studies it was not 
possible to find the abstract or the full text. This resulted in 101 articles. After reading the full 
texts, we excluded another 49 articles; 19 did not contain any clinical information and 30 had a 
largely overlapping study population.[4,12-40]  
Three pairs of studies had partially overlapping study populations, but unique data and hence 
were all included in the quantitative synthesis. Studies from Pedersen et al. [41] and Mygind et 
al. [42] described different symptoms in the same population. Studies from McManus et al. [43] 
and Jain et al. [44] had only a small partial overlap and provided mostly unique information. 
Papers by Shapiro et al. [45] and Davis et al. [46] had a partial overlap in study population but 
one described only situs anomalies and the other more clinical characteristics. In the end we 
included a total of 52 studies. 
Study characteristics 
Table 1 lists the included studies and describes their characteristics. The 51 articles [2,41-90] 
and one conference abstract [91] included, described a total of 1970 patients, with a mean 
number of 38 patients per study (range 10-168). Nearly half of the studies originated from 
paediatric clinics or peadiatric pulmonology departments, 11 came from ENT, 4 from adult 
pulmonology and 12 from other departments, such as diagnostic laboratories, radiology and 
pathology departments (Table 2). Two thirds were single-centre studies. More than half of the 
studies (56%) have been published in the last 10 years (≥2005).  Studies were relatively small, 
with most including less than 50 patients. Most studies (31) came from Europe, 10 from Asia, 8 
from North America, 2 from South America and 1 from Australia.  Seventeen studies included 
only children (<18 years), 3 only adults (≥18 years) and 32 studies described a study population 
of mixed age, consisting mainly of children with only few adults. Among those 32 studies, only 
11 described the clinical data stratified by age groups. Symptoms were assessed retrospectively 
in most studies (37, 71%). PCD diagnosis was established in different ways: 16 studies 
assessed ciliary ultrastructure only with EM and 29 with additional diagnostic tests (one or more 
of the following: nNO, VM and genetics). Five studies diagnosed patients only by clinical 
presentation; two did not describe the diagnostic evaluation of the patients. Most studies 
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described situs anomalies (92%), lower respiratory (92%) and upper respiratory symptoms 
(79%). Other manifestations and health problems were seldom reported: 17 studies (33%) 
reported on neonatal respiratory distress, 13 (25%) on congenital heart disease, 7 (14%) on 
infertility 3 (6%) on hydrocephalus, 2 (4%) on retinitis pigmentosa and none on renal symptoms.  
Prevalence of clinical manifestations 
Table S1 (online supplement) describes the prevalence of commonly reported clinical 
manifestations in the included studies, categorized by country of origin, including studies with 
overlapping populations. For all reported characteristics the prevalence varied widely between 
studies and our analysis showed considerable heterogeneity (I2 range: 68-94%). Figures 2-4 and 
online Figures S1-S11 describe prevalence of symptoms in the different studies. In the following 
text and figures we report all symptoms described in at least 5 studies. 
Situs anomalies 
Forty-one studies (79%) explicitly reported situs inversus and 7 (14%) reported only the cardiac 
situs of the patients or used the term situs ambiguus without any further specification. To 
calculate the prevalence, we summed these symptoms up under the designation of situs 
anomalies. After excluding studies that focused on describing patients with Kartagener 
syndrome, which had a high prevalence of situs anomalies (up to 100%), the prevalence of situs 
anomalies in the 43 eligible studies ranged from 11 to 90% (weighted mean: 49% with a 
heterogeneity of I2=71% and can be seen in Figure S1). 
Lower respiratory symptoms 
Cough was reported in 29 studies (55.8%) and prevalence varied from 14 to 100% with a 
weighted mean of 88% (Figure S2). Sputum production was reported for 15 to 100% of patients 
(weighted mean: 89%) in the 24 (46%) studies where it was described (Figure 2). Lower 
respiratory infections, including pneumonia were also common: reported in 27 studies (52%) 
with a weighted mean prevalence of 72% (range 15-100%, Figure S3). Prevalence of 
bronchiectasis (reported in 29 studies, 56%, after excluding studies focused in patients with 
Kartagener syndrome) ranged from 9 to 100%, with a weighted mean of 56% (Figure S4). The 
heterogeneity (I2) in prevalence of lower respiratory symptoms was ranging largely from 89% in 
sputum production to 94% in cough. 
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Upper respiratory symptoms 
Rhinitis, rhinorrhea or nasal congestion were assessed in 28 studies (54%) and ranged in 
prevalence from 9 to 100% (weighted mean: 75%, Figure S5). Otitis media (with or without 
effusion) was reported in 26 studies (50%) and its prevalence varied from 23 to 100% (weighted 
mean: 74%. Figure S6). Sinusitis was reported in 29 studies (56%, after excluding studies 
focusing on Kartagener syndrome) with a weighted mean of 69% (range: 10-100%, Figure S7). 
Hearing impairment was reported in 14 (27%) studies and prevalence ranged from 8 to 100% 
(weighted mean 36%, Figure 3). Insertion of grommets was reported by 12 studies (23%) and 
prevalence ranged from 5 to 92% (weighted mean: 55%, Figure S8). Nasal polyps were 
described in 14 studies (27%) and with a weighted mean of 19% (range 3-60%, Figure S9). The 
heterogeneity in prevalence of these upper respiratory symptoms and health problems ranged 
from 68% for nasal polyps to 93% for rhinitis and grommets’ insertion. 
Other symptoms 
Figure 4 shows the prevalence of congenital heart disease which was the only characteristic 
showing no heterogeneity (I2=0%) with a weighted mean of 5% (ranging from 3 to 8%) and was 
reported in 10 studies (19%, after excluding studies focusing on patients with Kartagener 
syndrome). Seventeen studies (33%) assessed neonatal respiratory distress and prevalence 
varied from 15 to 91% (weighted mean: 55%, Figure S10) Infertility was reported in 7 
publications (13.5%) which had a study population of adults or adults and children and it was 
assessed only on adult patients of these studies. Prevalence ranged from 15 to 79% (weighted 
mean: 30%, Figure S11). Of the 7 studies reporting on infertility, 4 stratified for sex. In these 4 
studies, 58% of women evaluated were infertile; male fertility was reported in 3 studies and 
100% of men evaluated in these studies were infertile. The heterogeneity in prevalence ranged 
from 0% in congenital heart disease to 91% in neonatal respiratory distress. Other symptoms 
reported in a small number of studies were recurrent headaches, fever episodes and 
gastroesophageal reflux. Other health conditions such as hydrocephalus and retinitis 
pigmentosa which have been described as rare manifestations of PCD were only reported in 3 
and 2 studies, respectively and renal manifestations were not reported in any of the studies.  
Differences in prevalence in different age groups and severity of symptoms 
The clinical manifestations assessed were rarely described stratified by sex or age group. The 
11 studies describing symptoms separately in adults and children included usually a small 
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number of adults and they had no further stratification in smaller age groups. No information on 
symptom severity was reported. 
Subgroup meta-analyses 
After excluding 7 studies where diagnosis was only based on clinical manifestations or where no 
information on diagnosis was available, subgroup meta-analyses performed in 45 studies with 
diagnosis proven by EM, or by EM plus other tests showed similar results to the ones presented. 
Weighted mean prevalence, range and heterogeneity of all symptoms from the subgroup meta-
analyses are presented in detail in Figures S12 to S25.  
Meta-regression 
Meta-regression showed that the explanatory factors considered explained only a small part of 
the between-studies variance for all symptoms.  Publication year explained some of the 
heterogeneity for sputum production and sinusitis, with a higher prevalence in studies published 
before 2004 (p-values: 0.06 and 0.005 respectively). Another factor that explained part of the 
heterogeneity was the type of clinic where the study originated from. Paediatric pulmonology and 
especially ENT clinics showed a higher prevalence of hearing impairment (p<0.0001) compared 
to general paediatric clinics. Age of included patients also explained part of the heterogeneity as 
situs anomalies and bronchiectasis were more common in studies including adults, or adults and 
children, compared to the ones including only children (p-values: 0.004 and 0.02 respectively). 
Bronchiectasis were also more common in prospective studies (p=0.03). Otitis media and 
hearing impairment had higher prevalence in studies where diagnosis was made by EM and 
other tests compared to the ones where diagnosis was only based on clinical symptoms. 
Detailed results of the meta-regression can be found in table S2. 
 
Discussion 
This is the first systematic review on clinical manifestations in PCD patients. We found a 
prevalence of 5% of congenital heart disease and a wide range in the prevalence of all other 
reported clinical symptoms. This heterogeneity could not be explained by the available 
explanatory factors. Only 7% of the originally identified 1210 studies described clinical 
manifestations of the disease and 30 reported overlapping study populations. Most studies were 
retrospective and small, with a mean of 38 patients per study. They often originated from 
specialised departments (e.g. pulmonary, ENT) and focused primarily on lower and upper 
respiratory symptoms. Less than half of the studies that included both children and adults 
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reported their information stratified by age. No study described symptom severity. Year of 
publication, clinic of origin, age of included patients, study design and diagnostic certainty were 
associated with symptom prevalence. 
The main strength of this study is the methodological approach: to identify eligible studies, the 
search was done without language restrictions and we included conference abstracts. Because 
some abstracts did not mention clinical manifestations, we screened the full text of all articles 
with an original PCD study population, even if clinical information was not explicitly mentioned in 
the abstracts. This ensured that we included studies we would have missed if we had followed 
the custom search protocol. We identified and excluded studies where the population inclusion 
criteria introduced a clear bias in the prevalence of certain manifestations. Additionally, we 
proceeded to explain the heterogeneity in results by performing a meta-regression with all 
available explanatory factors, but we were not able to include other known possible factors like 
personal interest of the authors. PCD diagnosis has changed over time and varies between 
countries and centres. For this reason, we performed a sensitivity analysis excluding all studies 
where the diagnosis had not been confirmed by recommended tests. 
We restricted our search to studies published since 1980 for several reasons. First, older studies 
were not easily available online or often do not have an available abstract on the online 
databases. Secondly, since 1933 when PCD was first described by Kartagener, many things 
have changed in diagnosing, understanding and characterising the disease. Thirdly, the studies 
that described clinical characteristics of PCD before 1980 were mostly case reports or small 
studies with less than 10 patients which would not be eligible for our review.  
The limitations of this review reflect the limitations of the included studies, namely inadequate 
study designs and the presence of significant selection and misclassification bias. With regards 
to study design, most studies were small, single center case series studies that collected clinical 
data retrospectively from patient charts. Three main sources of selection bias are apparent: (1) 
Diagnostic misclassification resulting from a wide variation of diagnostic criteria used in the 
studies, ranging from clinical diagnosis to diagnosis established by multiple available tests (EM, 
VM, nNO and genetics). Although there is still no established diagnostic gold standard for 
diagnosing PCD, the recommended diagnostic algorithm has changed considerably over the last 
years. To address this issue we performed subgroup meta-analyses excluding the studies where 
the diagnosis was only clinical or not described and we also tested the available diagnostic 
information as a possible explanatory factor of the heterogeneity in our meta-regression. (2) 
Since most studies originated from specialised clinics, it is expected that patients with more 
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severe manifestations were included and these study populations cannot be considered 
representative for all PCD patients. (3) Many studies had restrictive inclusion criteria, including 
e.g. only patients with situs anomalies or with reported otitis which would increase the 
prevalence of manifestations related to the selection criteria (ie. situs status and hearing 
impairment). Thus we excluded studies where the population inclusion criteria introduced a clear 
bias in the prevalence of certain manifestations (e.g. studies including only patients with 
Kartagener syndrome for the prevalence of situs anomalies, sinusitis and bronchiectasis). 
Misclassification bias is introduced when inconsistent criteria and different definitions are used to 
detect and define clinical manifestations. Most studies focused on symptoms from the upper and 
lower respiratory system. Other symptoms were rarely reported and hardly any study reported 
symptoms separately for different age groups. Therefore, it was not possible to describe 
changes in clinical picture throughout the life course. Information on symptom severity, such as 
frequency of cough or volume of sputum, was not reported. Data were collected at different 
points of disease; some at the time of diagnosis, others at a later follow-up appointment. As 
most studies suffered from the same design flaws, we did not apply any quality assessment 
criteria to decide which studies to include in our meta-analysis. 
Due to the considerable heterogeneity, the calculated mean weighted prevalence of described 
clinical manifestations characteristics (with the exception of congenital heart disease) should be 
interpreted with caution. The meta-analysis was done to quantify the variability in prevalence 
and not to give valid estimates on prevalence. The possible explanatory factors tested failed to 
explain this heterogeneity. Still some factors contributed to explaining differences in prevalence 
of some symptoms. Year of publication reflects differences in diagnosis but also increasing 
awareness of PCD. Older studies included more patients with severe disease. Age is one of the 
most important factors for health and disease. Situs anomalies and bronchiectasis were more 
common in adult patients, probably because cases without situs anomalies or severe lung 
disease were underdiagnosed in adults especially in the past. The type of clinic, where the study 
population originated from, can influence reported symptoms. The discovery of bronchiectasis 
could be highly influenced by study design; a standardised protocol for chest CT imaging and 
the existence of two evaluators of results instead of one are among the most important factors 
that could explain the higher prevalence in prospective studies. Diagnostic certainty was 
associated with higher prevalence of upper respiratory manifestations (otitis media and hearing 
impairment) in studies with test-proven diagnosis. Mild hearing impairment can remain 
undetected unless specific tests are performed, which could be more common after test-proven 
diagnosis. In addition, it is possible that unspecific upper respiratory symptoms play a less 
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important role to the differential diagnosis of PCD compared to situs anomalies and lower 
respiratory symptoms. The only outcome where the meta-analysis did not suggest heterogeneity 
(I2=0%) was congenital heart disease, where we found a prevalence of 5%. This is perhaps not 
surprising, since severe heart disease is diagnosed early in childhood in most cases. Hence it is 
likely that severe congenital heart defects are least susceptible to measurement bias.  The 
manifestations bronchiectasis, hearing impairment, and infertility would all be expected to have 
increased in frequency with time, with the uniform application of sensitive testing for detection 
(eg. Chest CT scanning, audiograms and spermatozoa analysis respectively). The variable 
“neonatal respiratory distress” is probably increasingly subject to recall bias as patients get 
older. We were unable to detect this in our meta-regression analysis (Table S2). However in one 
study [2], where uniform methods were applied to include cases prospectively, the prevalence of 
neonatal respiratory distress was much higher in children (87%) compared to adults (65%).  
In our study, methodological variability between included studies could not explain the 
heterogeneity in prevalence of manifestations. We believe that heterogeneity in prevalence is 
caused by the large variety of inclusion criteria and the insufficient standardisation of outcomes, 
which cannot be tested in a meta-analysis. Another possible explanation is  that patients with 
PCD might have several distinctive phenotypes, such as patients with CF [92,93] and with 
childhood asthma [94,95]; and the proportion of different phenotypes might vary between 
centres.    
Our review highlights the difficulty in describing the full clinical picture of PCD based on 
published studies. Future studies should conform to the following criteria: 
• report on all clinical manifestations, including the less common ones  
• assess indicators of symptoms severity 
• use clear, homogeneous definitions of all clinical manifestations 
• use clear inclusion criteria for the study population 
• collect data prospectively at specified assessment time points starting from diagnosis and 
continuing throughout life 
• stratify the analysis by the degree of diagnostic certainty of PCD of the patients.  
These criteria could be fulfilled by performing prospective well-designed multicenter studies in 
patients with carefully assessed PCD diagnosis. Another important resource will be the 
international PCD registry which has been established in the framework of the EU funded 
BESTCILIA project.[96]  
This carefully performed systematic review and meta-analysis of clinical manifestations of PCD 
found considerable heterogeneity between studies, not explained by methodological variations. 
15 
 
Further prospective studies with larger and carefully selected populations and well defined 
outcomes, will allow better characterization of the disease and possibly define different 
phenotypes of PCD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
References 
1. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, Bartoloni L, Eber E, Escribano A, 
Haarman E, Hesselmar B, Hogg C, Jorissen M, Lucas J, Nielsen KG, O'Callaghan C, Omran H, Pohunek P, 
Strippoli MP, Bush A. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment 
approaches in children. The European respiratory journal 2009;34:1264-76. 
2. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL, Hazucha M, Zariwala MA, Knowles MR. 
Primary Ciliary Dyskinesia: Diagnostic and Phenotypic Features. Am J Respir Crit Care Med 2004;169:459-
67. 
3. Lucas JS, Walker WT, Kuehni CE, al. e. Primary Ciliary Dyskinesia. In: Courdier J-F, editor Orphan 
Lung diseases European Respiratory Monograph 2011:201-17. 
4. Turner JA, Corkey CW, Lee JY, Levison H, Sturgess J. Clinical expressions of immotile cilia 
syndrome. Pediatrics 1981;67:805-10. 
5. Boon M, Jorissen M, Proesmans M, De Boeck K. Primary ciliary dyskinesia, an orphan disease. Eur 
J Pediatr 2013;172:151-62. 
6. Kuehni CE, Frischer T, Strippoli MP, Maurer E, Bush A, Nielsen KG, Escribano A, Lucas JS, 
Yiallouros P, Omran H, Eber E, O'Callaghan C, Snijders D, Barbato A, Children ERSTFoPCDi. Factors 
influencing age at diagnosis of primary ciliary dyskinesia in European children. The European respiratory 
journal 2010;36:1248-58. 
7. Strippoli MP, Frischer T, Barbato A, Snijders D, Maurer E, Lucas JS, Eber E, Karadag B, Pohunek P, 
Zivkovic Z, Escribano A, O'Callaghan C, Bush A, Kuehni CE, Children ERSTFoCDi. Management of primary 
ciliary dyskinesia in European children: recommendations and clinical practice. The European respiratory 
journal 2012;39:1482-91. 
8. Miller JJ. The inverse of the Freeman–Tukey double arcsine transformation. The American 
Statistician 1978;32:138-. 
9. Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals 
of Mathematical Statistics 1950:607-11. 
10. Higgins J, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. 
Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009;172:137-59. 
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 
2002;21:1539-58. 
12. Chao J, Turner JA, Sturgess JM. Genetic heterogeneity of dynein-deficiency in cilia from patients 
with respiratory disease. Am Rev Respir Dis 1982;126:302-5. 
13. Levison HM, C. M.; Chao, J.; Turner, J. A.; Sturgess, J. M.; Stringer, D. A. Pathophysiology of the 
ciliary motility syndromes. Eur J Respir Dis Suppl 1983;127:102-17. 
14. Nadel HR, Stringer DA, Levison H. The immotile cilia syndrome: Radiological manifestations. 
Radiology 1985;154:651-5. 
15. Mygind NP, M.; Nielsen, M. H. Primary and secondary ciliary dyskinesia. Acta Otolaryngol 
1983;95:688-94. 
16. Pedersen MM, N. Rhinitis, sinusitis and otitis media in Kartagener's syndrome (primary ciliary 
dyskinesia). Clin Otolaryngol Allied Sci 1982;7:373-80. 
17. Armengot M, Juan G, Barona R, Garin L, Basterra J. Immotile cilia syndrome: Nasal mucociliary 
function and nasal ciliary abnormalities. Rhinology 1994;32:109-11. 
18. Carda C, Armengot M, Escribano A, Peydro A. Ultrastructural patterns of primary ciliar dyskinesia 
syndrome. Ultrastruct Pathol 2005;29:3-8. 
19. Armengot Carceller MCB, C.; Escribano, A.; Samper, G. J. [Study of mucociliary transport and 
nasal ciliary ultrastructure in patients with Kartagener's syndrome]. Arch Bronconeumol 2005;41:11-5. 
17 
 
20. Barranco MJ, Armengot M, Carda C, Ciscar MA, Peris R, Ramon M, Juan G. The primary ciliary 
dyskinesia syndrome. A frequent pathology. Arch Bronconeumol 1994;30:19-22. 
21. Pifferi M, Bush A, Michelucci A, Di Cicco M, Piras M, Caramella D, Mazzei F, Neri M, Pioggia G, 
Tartarisco G, Saggese G, Simi P, Boner AL. Mannose-binding lectin 2 gene polymorphism and lung 
damage in primary ciliary dyskinesia. Pediatr Pulmonol 2014. 
22. Santamaria FE, M.; Montella, S.; Cantone, E.; Mollica, C.; De Stefano, S.; Mirra, V.; Carotenuto, 
M. Sleep disordered breathing and airway disease in primary ciliary dyskinesia. Respirology 2014;19:570-
5. 
23. Mirra V, Caffarelli C, Maglione M, Valentino R, Perruolo G, Mazzarella C, Di Micco LL, Montella S, 
Santamaria F. Hypovitaminosis D: a novel finding in primary ciliary dyskinesia. Italian journal of pediatrics 
2015;41:14. 
24. Gokdemir YK-S, E.; Erdem, E.; Bayindir, O.; Ersu, R.; Karadag, B.; Sekban, N.; Akyuz, G.; Karakoc, F. 
Comparison of conventional pulmonary rehabilitation and high-frequency chest wall oscillation in 
primary ciliary dyskinesia. Pediatr Pulmonol 2014;49:611-6. 
25. Rollin M, Seymour K, Hariri M, Harcourt J. Rhinosinusitis, symptomatology & absence of 
polyposis in children with primary ciliary dyskinesia. Rhinology 2009;47:75-8. 
26. Coren ME, Meeks M, Morrison I, Buchdahl RM, Bush A. Primary ciliary dyskinesia: Age at 
diagnosis and symptom history. Acta Paediatrica, International Journal of Paediatrics 2002;91:667-9. 
27. Munro NC, Currie DC, Lindsay KS, Ryder TA, Rutman A, Dewar A, Greenstone MA, Hendry WF, 
Cole PJ. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. Thorax 
1994;49:684-7. 
28. Greenstone MS, P.; Cole, P.; Mackay, I. Upper airway manifestations of primary ciliary dyskinesia. 
Journal of Laryngology and Otology 1985;99:985-91. 
29. Engesaeth VG, Warner JO, Bush A. New associations of primary ciliary dyskinesia syndrome. 
Pediatr Pulmonol 1993;16:9-12. 
30. Pruliere-Escabasse V, Coste A, Chauvin P, Fauroux B, Tamalet A, Garabedian EN, Escudier E, 
Roger G. Otologic features in children with primary ciliary dyskinesia. Archives of Otolaryngology - Head 
and Neck Surgery 2010;136:1121-6. 
31. Blanchon S, Legendre M, Copin B, Duquesnoy P, Montantin G, Kott E, Dastot F, Jeanson L, 
Cachanado M, Rousseau A, Papon JF, Beydon N, Brouard J, Crestani B, Deschildre A, Desir J, Dollfus H, 
Leheup B, Tamalet A, Thumerelle C, Vojtek AM, Escalier D, Coste A, de Blic J, Clement A, Escudier E, 
Amselem S. Delineation of CCDC39/CCDC40 mutation spectrum and associated phenotypes in primary: 
Ciliary dyskinesia. J Med Genet 2012;49:410-6. 
32. Tamalet A, Clement A, Roudot-Thoraval F, Desmarquest P, Roger G, Boule M, Millepied MC, 
Baculard TA, Escudier E. Abnormal central complex is a marker of severity in the presence of partial 
ciliary defect. Pediatrics 2001;108:E86. 
33. Pittman JER, M.; LaFave, C.; Ferkol, T.; Milla, C. E.; Sagel, S.; Dell, S.; Jones, P.; Johnson, R. C.; 
Leigh, M.; Knowles, M. R.; Davis, S. D. Characteristics of primary ciliary dyskinesia in children under 5 
years of age. Am J Respir Crit Care Med 2011;183. 
34. Ferkol TW, Puffenberger EG, Lie H, Helms C, Strauss KA, Bowcock A, Carson JL, Hazucha M, 
Morton DH, Patel AC, Leigh MW, Knowles MR, Zariwala MA. Primary ciliary dyskinesia-causing mutations 
in Amish and Mennonite communities. Journal of Pediatrics 2013;163:383-7. 
35. Shapiro AJD, S. D.; Olivier, K. N.; Ferkol, T. W.; Dell, S. D.; Sagel, S. D.; Rosenfeld, M.; Milla, C. E.; 
Atkinson, J. J.; Knowles, M. R.; Leigh, M. W. Clinical symptoms associated with primary ciliary dyskinesia - 
Results of a multi-centered study. Am J Respir Crit Care Med 2010;181. 
36. Shapiro AJ, Tolleson-Rinehart S, Zariwala MA, Knowles MR, Leigh MW. The prevalence of clinical 
features associated with primary ciliary dyskinesia in a heterotaxy population: results of a web-based 
survey. Cardiology in the young 2014:1-8. 
18 
 
37. Knowles MRO, L. E.; Leigh, M. W.; Sears, P. R.; Davis, S. D.; Wolf, W. E.; Hazucha, M. J.; Carson, J. 
L.; Olivier, K. N.; Sagel, S. D.; Rosenfeld, M.; Ferkol, T. W.; Dell, S. D.; Milla, C. E.; Randell, S. H.; Yin, W.; 
Sannuti, A.; Metjian, H. M.; Noone, P. G.; Noone, P. J.; Olson, C. A.; Patrone, M. V.; Dang, H.; Lee, H. S.; 
Hurd, T. W.; Gee, H. Y.; Otto, E. A.; Halbritter, J.; Kohl, S.; Kircher, M.; Krischer, J.; Bamshad, M. J.; 
Nickerson, D. A.; Hildebrandt, F.; Shendure, J.; Zariwala, M. A. Mutations in RSPH1 cause primary ciliary 
dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med 2014;189:707-17. 
38. Kim RHAHDC, E.; Knowles, M. R.; Nelligan, K. A.; Nykamp, K.; Zariwala, M. A.; Dell, S. D. The role 
of molecular genetic analysis in the diagnosis of primary ciliary dyskinesia. Annals of the American 
Thoracic Society 2014;11:351-9. 
39. Boon MDB, K.; Jorissen, M.; Meyts, I. Primary ciliary dyskinesia and humoral immunodeficiency--
is there a missing link? Respir Med 2014;108:931-4. 
40. van der Baan SV, A. J.; Weltevreden, E. F.; Feenstra, L. Kartagener's syndrome: clinical symptoms 
and laboratory studies. Eur J Respir Dis Suppl 1983;127:91-5. 
41. Pedersen MS, G. Bronchopulmonary symptoms in primary ciliary dyskinesia. A clinical study of 27 
patients. Eur J Respir Dis Suppl 1983;127:118-28. 
42. Mygind NP, M. Nose-, sinus- and ear-symptoms in 27 patients with primary ciliary dyskinesia. Eur 
J Respir Dis Suppl 1983;127:96-101. 
43. McManus IC, Mitchison HM, Chung EM, Stubbings GF, Martin N. Primary ciliary dyskinesia 
(Siewert's/Kartagener's syndrome): respiratory symptoms and psycho-social impact. BMC Pulm Med 
2003;3:4. 
44. Jain K, Padley SP, Goldstraw EJ, Kidd SJ, Hogg C, Biggart E, Bush A. Primary ciliary dyskinesia in 
the paediatric population: range and severity of radiological findings in a cohort of patients receiving 
tertiary care. Clin Radiol 2007;62:986-93. 
45. Shapiro AJ, Davis SD, Ferkol T, Dell SD, Rosenfeld M, Olivier KN, Sagel SD, Milla C, Zariwala MA, 
Wolf W, Carson JL, Hazucha MJ, Burns K, Robinson B, Knowles MR, Leigh MW. Laterality defects other 
than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest 
2014;146:1176-86. 
46. Davis SD, Ferkol TW, Rosenfeld M, Lee HS, Dell SD, Sagel SD, Milla C, Zariwala MA, Pittman JE, 
Shapiro AJ, Carson JL, Krischer JP, Hazucha MJ, Cooper ML, Knowles MR, Leigh MW. Clinical features of 
childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. American journal of 
respiratory and critical care medicine 2015;191:316-24. 
47. Afzelius BAE, R. Male and female infertility problems in the immotile-cilia syndrome. Eur J Respir 
Dis Suppl 1983;127:144-7. 
48. Alsaadi MM, Habib SS, Al Muqhem BA, Aldrees A, Al Zamil JF, Alsadoon HA. Significance of 
fractional exhaled nitric oxide measurements in detecting primary ciliary dyskinesia in Saudi children. 
Saudi Med J 2013;34:24-8. 
49. Armengot M, Bonet M, Carda C, Gomez MJ, Milara J, Mata M, Cortijo J. Development and 
validation of a method of cilia motility analysis for the early diagnosis of primary ciliary dyskinesia. Acta 
Otorrinolaringol Esp 2012;63:1-8. 
50. Armengot M, Juan G, Carda C, Basterra J, Cano B. The prevalence of primary dyskinetic ciliary 
syndromes in patients with sinusitis and bronchiectasis. An Otorrinolaringol Ibero Am 1995;22:85-92. 
51. Bai Y, Zhang J, You S, Ji L, Jia J, Wang H. [Clinical characteristics of primary ciliary dyskinesia]. 
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2014;49:115-20. 
52. Barlocco EG, Valletta EA, Canciani M, Lungarella G, Gardi C, De Santi MM, Mastella G. 
Ultrastructural ciliary defects in children with recurrent infections of the lower respiratory tract. Pediatr 
Pulmonol 1991;10:11-7. 
53. Beucher J, Chambellan A, Segalen J, Deneuville E. [Primary ciliary dyskinesia: a retrospective 
review of clinical and paraclinical data]. Rev Mal Respir 2011;28:856-63. 
19 
 
54. Braun JJD, L.; Clavert, A.; Cranz, C.; Hoffmann, L.; Gentine, A. [Primary ciliary dyskinesia. Clinical 
presentation and diagnosis]. Ann Otolaryngol Chir Cervicofac 2005;122:63-8. 
55. Busquets RM, Caballero-Rabasco MA, Velasco M, Lloreta J, Garcia-Algar O. Primary Ciliary 
Dyskinesia: Clinical Criteria Indicating Ultrastructural Studies. Arch Bronconeumol 2013;49:99-104. 
56. Camner PM, B.; Afzelius, B. A. Measurements of tracheobronchial clearance in patients with 
immotile-cilia syndrome and its value in differential diagnosis. Eur J Respir Dis Suppl 1983;127:57-63. 
57. de Boode WP, Collins JM, Veerman AJ, van der Baan S. Primary ciliary dyskinesia; a questionnaire 
study of the clinical aspects. Ned Tijdschr Geneeskd 1989;133:2338-41. 
58. El-Sayed Y, Al-Sarhani A, Al-Essa AR. Otological manifestations of primary ciliary dyskinesia. Clin 
Otolaryngol Allied Sci 1997;22:266-70. 
59. Goyal RJ, A.; Raghu, M.; Gupta, R.; Singla, R.; Gupta, N.; Menon, M. P. Clinical profile of eleven 
patients of Kartagener's syndrome--certain interesting associations. Indian J Chest Dis Allied Sci 
1987;29:150-9. 
60. Greenstone MR, A.; Dewar, A.; Mackay, I.; Cole, P. J. Primary ciliary dyskinesia: cytological and 
clinical features. Q J Med 1988;67:405-23. 
61. Hellinckx J, Demedts M, De Boeck K. Primary ciliary dyskinesia: Evolution of pulmonary function. 
Eur J Pediatr 1998;157:422-6. 
62. Holzmann D, Felix H. Neonatal respiratory distress syndrome--a sign of primary ciliary 
dyskinesia? Eur J Pediatr 2000;159:857-60. 
63. Iniguez CR, Fonseca AX, Hernandez CJ, Gonzalez BS, Sanchez DI. [Clinical and ultrastructural 
features of ciliary dyskinesia]. Rev Med Chil 2007;135:1147-52. 
64. Kawakami M, Hattori Y, Nakamura S. Reflection of structural abnormality in the axoneme of 
respiratory cilia in the clinical features of immotile cilia syndrome. Intern Med 1996;35:617-23. 
65. Korppi M, Dunder T, Remes S, Sjostrom PM, Holm T, Vahasarja V, Jartti T, Paakko P, Kajosaari M. 
[Congenital ciliary dysfunction in children]. Duodecim 2011;127:2294-302. 
66. Lesic I, Maurer E, Strippoli MP, Kuehni CE, Barbato A, Frischer T, children ERSToPCDi. [Primary 
ciliary dyskinesia (Pcd) in Austria]. Wiener klinische Wochenschrift 2009;121:616-22. 
67. Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary ciliary 
dyskinesia: A cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010;181:1262-
8. 
68. Min YG, Shin JS, Choi SH, Chi JG, Yoon CJ. Primary ciliary dyskinesia: Ultrastructural defects and 
clinical features. Rhinology 1995;33:189-93. 
69. Montella SS, F.; Salvatore, M.; Maglione, M.; Iacotucci, P.; De Santi, M. M.; Mollica, C. Lung 
disease assessment in primary ciliary dyskinesia: a comparison between chest high-field magnetic 
resonance imaging and high-resolution computed tomography findings. Ital J Pediatr 2009;35:24. 
70. O'Callaghan C, Chetcuti P, Moya E. High prevalence of primary ciliary dyskinesia in a British Asian 
population. Arch Dis Child 2010;95:51-2. 
71. Oktem S, Karadag B, Erdem E, Gokdemir Y, Karakoc F, Dagli E, Ersu R. Sleep disordered breathing 
in patients with primary ciliary dyskinesia. Pediatr Pulmonol 2013;48:897-903. 
72. Olm MA, Kogler JE, Jr., Macchione M, Shoemark A, Saldiva PH, Rodrigues JC. Primary ciliary 
dyskinesia: evaluation using cilia beat frequency assessment via spectral analysis of digital microscopy 
images. J Appl Physiol (1985) 2011;111:295-302. 
73. Pifferi M, Bush A, Di Cicco M, Pradal U, Ragazzo V, Macchia P, Boner AL. Health-related quality of 
life and unmet needs in patients with primary ciliary dyskinesia. European Respiratory Journal 
2010;35:787-94. 
74. Plesec TP, Ruiz A, McMahon JT, Prayson RA. Ultrastructural abnormalities of respiratory cilia: A 
25-year experience. Archives of Pathology and Laboratory Medicine 2008;132:1786-91. 
75. Rachinskii SV, Volkov IK, Sereda EV, Alekseevskikh Iu G, Lukina OF, Marinushkin AM. [The Zivert-
Kartagener syndrome in children]. Probl Tuberk 1993:19-22. 
20 
 
76. Rutishauser M. Clinical features of primary ciliary dyskinesia. Schweiz Med Wochenschr 
2000;130:705-10. 
77. Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial 
in patients with primary ciliary dyskinesia? Chest 1996;109:1541-4. 
78. Sommer JU, Schafer K, Omran H, Olbrich H, Wallmeier J, Blum A, Hormann K, Stuck BA. ENT 
manifestations in patients with primary ciliary dyskinesia: Prevalence and significance of 
otorhinolaryngologic co-morbidities. European Archives of Oto-Rhino-Laryngology 2011;268:383-8. 
79. Sturgess JM, Thompson MW, Czegledy-Nagy E, Turner JA. Genetic aspects of immotile cilia 
syndrome. Am J Med Genet 1986;25:149-60. 
80. Tolusakow WL, Boikow GA, Lewaschow JN, Schirjaewa KF, Kartawowa WA. [Bronchiectasis in 
patients with situs inversus viscerum (Kartagener syndrome) (author's transl)]. Z Erkr Atmungsorgane 
1981;156:167-75. 
81. Vallet C, Escudier E, Roudot-Thoraval F, Blanchon S, Fauroux B, Beydon N, Boule M, Vojtek AM, 
Amselem S, Clement A, Tamalet A. Primary ciliary dyskinesia presentation in 60 children according to 
ciliary ultrastructure. Eur J Pediatr 2013;172:1053-60. 
82. van der Baan S. Primary ciliary dyskinesia and the middle ear. Laryngoscope 1991;101:751-4. 
83. Wang LFG, Y. B.; Gu, Y. Y.; Zeng, Q. S.; Chen, L.; Zhang, C. L.; He, J. X.; Zhong, N. S. Bronchiolitis in 
Kartagener syndrome: Imaging diagnosis and following up. Chinese Journal of Medical Imaging 
Technology 2009;25:2040-2. 
84. Wolter NE, Dell SD, James AL, Campisi P. Middle ear ventilation in children with primary ciliary 
dyskinesia. Int J Pediatr Otorhinolaryngol 2012;76:1565-8. 
85. Xu BP, Shen KL, Hu YH, Feng XL, Li HM, Lang ZQ. [Clinical characteristics of primary ciliary 
dyskinesia in children]. Zhonghua Er Ke Za Zhi 2008;46:618-22. 
86. Yiallouros PK, Kouis P, Middleton N, Nearchou M, Adamidi T, Georgiou A, Eleftheriou A, Ioannou 
P, Hadjisavvas A, Kyriacou K. Clinical features of primary ciliary dyskinesia in Cyprus with emphasis on 
lobectomized patients. Respiratory medicine 2015;109:347-56. 
87. Mullowney T, Manson D, Kim R, Stephens D, Shah V, Dell S. Primary ciliary dyskinesia and 
neonatal respiratory distress. Pediatrics 2014;134:1160-6. 
88. Boon MS, A.; Cuppens, H.; Jaspers, M.; Proesmans, M.; Dupont, L. J.; Vermeulen, F. L.; Van Daele, 
S.; Malfroot, A.; Godding, V.; Jorissen, M.; De Boeck, K. Primary ciliary dyskinesia: critical evaluation of 
clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure. Orphanet journal 
of rare diseases 2014;9:11. 
89. Chin GY, Karas DE, Kashgarian M. Correlation of presentation and pathologic condition in primary 
ciliary dyskinesia. Archives of Otolaryngology - Head and Neck Surgery 2002;128:1292-4. 
90. Hosie PF, D. A.; Jaffe, A.; Birman, C. S.; Morgan, L. Primary ciliary dyskinesia: Overlooked and 
undertreated in children. J Paediatr Child Health 2014. 
91. Enderby BJD, M.; Heaver, R. A cross-sectional analysis of children treated for primary ciliary 
dyskinesia at birmingham children's hospital. Am J Respir Crit Care Med 2010;181. 
92. Durno C, Corey M, Zielenski J, Tullis E, Tsui L-C, Durie P. Genotype and phenotype correlations in 
patients with cystic fibrosis and pancreatitis. Gastroenterology 2002;123:1857-64. 
93. Hubert D, Bienvenu T, Desmazes-Dufeu N, Fajac I, Lacronique J, Matran R, Kaplan J, Dusser D. 
Genotype-phenotype relationships in a cohort of adult cystic fibrosis patients. European Respiratory 
Journal 1996;9:2207-14. 
94. Spycher B, Silverman M, Kuehni C. Phenotypes of childhood asthma: are they real? Clinical & 
Experimental Allergy 2010;40:1130-41. 
95. Spycher BD, Henderson J, Granell R, Evans DM, Smith GD, Timpson NJ, Sterne JA. Genome-wide 
prediction of childhood asthma and related phenotypes in a longitudinal birth cohort. Journal of Allergy 
and Clinical Immunology 2012;130:503-9. e7. 
21 
 
96. Werner C, Lablans M, Ataian M, Raidt J, Wallmeier J, Grosse-Onnebrink J, Kuehni CE, Haarman 
EG, Leigh MW, Quittner AL, Lucas JS, Hogg C, Witt M, Priftis KN, Yiallouros P, Nielsen KG, Santamaria F, 
Uckert F, Omran H. An international registry for primary ciliary dyskinesia. Eur Respir J 2016;47:849-59. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
Legends 
 
Figure 1: Flow chart describing the selection procedure. 
 
Figure 2: Sputum production in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in the included publications. 
 
Figure 3: Hearing impairment in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in the included publications. 
 
Figure 4: Congenital heart disease in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in the included publications. 
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Supplementary Files: 
 
TABLE S1: Prevalence of reported characteristics of PCD by country, including studies with 
overlapping population. 
TABLE S2: Meta-regression results on prevalence of reported clinical characteristics of PCD 
patients. 
 
Figure S1: Situs anomalies in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in the included publications. 
Figure S2: Cough in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in the included publications.in the included publications. 
Figure S3: Lower respiratory infections in PCD patients: Forest plot showing the heterogeneity 
and weighted mean prevalence in the included publications. 
Figure S4: Bronchiectasis in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in the included publications. 
Figure S5: Rhinitis in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in the included publications. 
Figure S6: Otitis in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in the included publications. 
Figure S7: Sinusitis in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in the included publications. 
Figure S8: Use of grommets in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in the included publications. 
Figure S9: Nasal polyps in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in the included publications. 
Figure S10: Neonatal respiratory distress in PCD patients: Forest plot showing the heterogeneity 
and weighted mean prevalence in the included publications. 
Figure S11: Infertility in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in the included publications. 
Figure S12: Situs anomalies in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S13: Cough in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in publications included in subgroup meta-analysis. 
Figure S14: Sputum production in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S15: Lower respiratory infections in PCD patients: Forest plot showing the heterogeneity 
and weighted mean prevalence in publications included in subgroup meta-analysis. 
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Figure S16: Bronchiectasis in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in publications included in subgroup meta-analysis. 
Figure S17: Rhinitis in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in publications included in subgroup meta-analysis. 
Figure S18: Otitis media in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in publications included in subgroup meta-analysis. 
Figure S19: Sinusitis in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in publications included in subgroup meta-analysis. 
Figure S20: Hearing impairment in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S21: Insertion of grommets in PCD patients: Forest plot showing the heterogeneity and 
weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S22: Nasal polyps in PCD patients: Forest plot showing the heterogeneity and weighted 
mean prevalence in publications included in subgroup meta-analysis. 
Figure S23: Congenital heart disease in PCD patients: Forest plot showing the heterogeneity 
and weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S24: Neonatal respiratory distress in PCD patients: Forest plot showing the heterogeneity 
and weighted mean prevalence in publications included in subgroup meta-analysis. 
Figure S25: Infertility in PCD patients: Forest plot showing the heterogeneity and weighted mean 
prevalence in publications included in subgroup meta-analysis. 
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TABLE 1: Detailed characteristics of included studies describing clinical manifestations of PCD, stratified by age group of participants  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
  
  
 
 
 
 
Children                     
AL SAADI et al. S. Arabia 2013 22 11#(-)  paediatrics case-control R EM+nNO - - + + + - - - 
BARLOCCO et al. Italy 1991 28 8#(0-18) paed. pulmonology case series P EM - - + + + - - - 
BEUCHER et al. France 2011 17 7#(-) paed. pulmonology case series R EM+nNO - - + - + + - - 
BUSQUETS et al. Spain 2013 35 - paed. pulmonology case series R EM - - - + - - - - 
DAVIS et al. USA 2015 118 8#(5-11) combination case series P EM+nNO+Genetics - - + + + + - - 
ENDERBY et al.+ England 2010 17 9¶(4-17) paediatrics case series R only clinical - - + + + + - - 
HOSIE et al. Australia 2015 84 6¶(0-18) paediatrics cohort R EM+VM+nNO - - + + + + + - 
JAIN et al. England 2007 89 - paed. pulmonology case series R EM+VM+nNO - - + + + + - - 
KORPPI et al. Finland 2011 12 -  paediatrics cohort R EM - - + + - - - - 
MIN et al. S. Korea 1995 19 10#(5-15) paediatrics case series R EM - - + + + - - - 
MULLOWNEY et al.  Canada 2014 55 11#(-) paed. pulmonology case-control R EM+nNO+Genetics - - + + - + + - 
O'CALLAGHAN et al. England 2010 19 - PCD diagnostic centre case series R EM+VM - - + + - + - - 
RACHINSKII et al. Russia 1993 24 - Paediatrics case series R EM - - + + + - + - 
RUTISHAUSER Switzerland 2000 30 - Paediatrics case series R EM+VM - - + + + - + - 
VALLET et al. France 2013 60 - (0-15) paed. pulmonology case series R EM+VM - - + + + + - - 
WOLTER et al. Canada 2012 31 7#(0-17) ENT case series R EM+nNO - - + + + + - - 
XU et al. China 2008 26 - paediatrics case series R EM - - + + + - - - 
                      
Adults                     
AFZELIUS et al. Sweden 1983 29 - PCD diagnostic centre case series R EM - - + - - - - + 
CAMNER et al.+ Sweden 1983 20 30#(19-40) adult pulmonology case series R only clinical - - + + + - - - 
SMIT et al. Canada 1996 21 46#(24-66 adult pulmonology case series R EM+VM - - + + - - - - 
EM: electron microscopy, VM: light or high frequency video-microscopy, nNO: nasal NO, R: information on symptoms were collected retrospectively and P: prospectively, “-“: information not reported in the publication 
Age is reported in years as mean# (range) or median¶ (range) depending on the available information  
+ studies excluded from subgroup meta-analyses 
  
TABLE 1: Detailed characteristics of included studies describing clinical manifestations of PCD, stratified by age group of participants  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
  
  
 
 
 
 
Children and adults 
  
                  
ARMENGOT et al. Spain 2012 25 28#(1-66)  ENT case series P EM+VM + - + + + - - - 
ARMENGOT et al. Spain 1995 14 24#(5-50) ENT case series P EM - - + + + - - - 
BAI et al.  China 2014 10 35#(6-56) ENT case series R EM+nNO+Genetics + - + + + - - + 
BOON et al. Belgium 2014 168 18¶(-) PCD diagnostic centre cohort R EM+VM+nNO+Genetics - - + + + + + - 
BRAUN et al. France 2005 35 - ENT case series R EM+VM - - + + - + + - 
CHIN et al. China 2002 73 - (0-48) pathology case series R EM+nNO - -  + + - - - 
DE BOODE et al. Netherlands 1989 34 23#(6-55) paediatric case series R EM+VM - - + + + - - - 
EL-SAYED et al. S. Arabia 1997 16 18#(2-46) ENT case series P EM + - + + + - - - 
GOYAL et al.+ India 1987 11 - adult pulmonology case series R only clinical + - + + + - - - 
GREENSTONE et al. England 1988 30 19#(0-51) cardiothoracic case series P EM+VM - - + + + - - + 
HELLINCKX et al. Belgium 1998 12 - (1-32) paed. pulmonology case series R EM+VM - - - + - - - - 
HOLZMANN et al. Switzerland 2000 10 - ENT case series R EM+VM - - + + + + - - 
INIGUEZ et al. Chile 2007 33 - ENT case series R EM - - + + + - - - 
KAWAKAMI et al. Japan 1996 48 38#(17-72) paed. pulmonology case series R EM - - + + + - - - 
LESIC et al. Austria 2009 13 - paediatrics case series R EM - - + + + - - + 
MARTHIN et al. Denmark 2010 74 19¶(6-70) PCD reference centre case series R EM+VM+nNO - - + + + + + - 
MCMANUS et al.+ England 2003 93 23#(4-66) psychology case series P - - - + + + - - - 
MONTELLA et al. Italy 2009 13 15¶(10-29) paediatrics case series P EM+VM + - + + - + - - 
MYGIND et al.+ Denmark 1983 27 24#(4-56) ENT case series P only clinical + - + + + - - - 
NOONE et al. USA 2004 78 27#(1-73) combination case series P EM+VM+nNO + - + + + + - - 
OKTEM et al. Turkey 2013 29 10#(0-24) paediatrics case-control P EM - - - + + - - - 
OLM et al.  Brazil 2011 12 12#(1-19) paed. pulmonology case series R EM + - + + - - + - 
PEDERSEN et al. Denmark 1983 27 - paediatrics case series P EM+VM + - + + +   + + 
PIFFERI et al. Italy 2010 78 21#(2-49) paediatrics case series P EM+VM - - + + + - + - 
PLESEC et al. USA 2008 13 15#(1-49) pathology case series R EM + - + + + - + + 
SHAPIRO et al. USA 2014 35 18#(2-58) combination case series R EM+nNO+Genetics - - + + + + + - 
SOMMER et al.+ Germany 2011 44 29#(-) ENT case series R - 
 
- - + - + - - - 
STURGESS et al. Canada 1986 46 - paediatrics case series R EM+Genetics + - + + + - - - 
TOLUSAKOW et al.+ Russia 1981 23 - (3-43) adult pulmonology case series P only clinical - - + + + - - - 
VAN DER BAAN et al. Netherlands 1991 36 25#(1-59) ENT case series P EM+VM - - + - - - - - 
WANG et al. China 2009 24 29#(4-63) radiology case series R EM - - + + + - + + 
YIALLOUROS et al. Cyprus 2015 30 24#(1-64) paediatrics cohort R EM+VM+nNO - - + + + + - - 
EM: electron microscopy, VM: light or high frequency video-microscopy, nNO: nasal NO, R: information on symptoms were collected retrospectively and P: prospectively, “-“: information not reported in the publication 
Age is reported in years as mean# (range) or median¶ (range) depending on the available information  
+ studies excluded from subgroup meta-analyses 
 TABLE 2: Characteristics of included studies reporting clinical manifestations of PCD 
Characteristic Studies (n=52) Proportion of studies (%) 
   
Type of clinic     
Paediatric department 16 33 
Paediatric pulmonology department 9 17 
Adult pulmonology department 4 8 
ENT department 11 21 
Other departement 12 21 
   
Number of centres     
Singlecentre 35 66 
Multicentre 17 33 
   
Publication period     
≤1994 12 23 
1995-2004 11 21 
≥2005 29 56 
   
Study size   
≤20 patients 15 29 
21-50 patients 25 48 
50-100 patients 9 14 
>100 patients 3 6 
   
Study region     
Europe 31 60 
Asia 10 19 
North America 8 15 
South America 2 4 
Australia 1 2 
   
Age of participants     
Children <18 years 17 33 
Adults ≥18 years 3 6 
Children and adults 32 62 
   
Study design   
Retrospective 37 71 
Prospective 15 29 
 
 
TABLE 2: Characteristics of included studies reporting clinical manifestations of PCD 
Characteristic Studies (n=52)  Proportion of studies (%)  
   
Diagnostics performed    
Only clinical diagnosis 5 10 
Diagnosis proven by EM 16 31 
Diagnosis proven by EM plus other tests¶ 29 56 
Not available information on diagnostics 2 4 
   
   
Health conditions   
Situs anomalies 48 92 
Lower respiratory conditions 48 92 
           Cough 29 56 
           Sputum production 24 46 
           Lower respiratory tract infections 27 52 
           Bronchiectasis 34 65 
Upper respiratory conditions 41 79 
           Rhinitis 28 54 
           Otitis media 26 50 
           Sinusitis 32 62 
           Hearing impairment 14 27 
           Grommets 12 23 
           Nasal polyps 14 27 
Other conditions   
           Neonatal respiratory distress 17 33 
           Congenital heart disease 13 25 
           Infertility 7 14 
           Hydrocephalus 3 6 
           Retinitis pigmentosa 2 4 
           Renal symptoms  0 0  
   
Information for different age groups 11# 34 
Information on severity 0 0 
EM: electron microscopy 
¶ one or more of the following: nasal NO, high frequency videomicroscopy or light microscopy, genetics 
# of 32 studies including children and adults 
 
